Publication Name	World Journal of Anesthesiology
Manuscript ID	19770
Country	United Kingdom

Received	2015-05-20 16:36
Peer-Review Started	2015-05-22 09:41
To Make the First Decision	2015-07-02 13:30
Return for Revision	2015-07-10 14:39
Revised	2015-07-20 06:34
Second Decision	2015-08-13 10:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-08-21 16:18
Articles in Press	2015-08-21 16:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-13 18:41
Publish the Manuscript Online	2015-11-26 17:20

ISSN	2218-6182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Anesthesiology
Manuscript Type	Minireviews
Article Title	Sugammadex: Role in current anaesthetic practice and its safety benefits for patients
Manuscript Source	Invited Manuscript
All Author List	Michael V Copp and Thomas F Barrett
Funding Agency and Grant Number
Corresponding Author	Dr. Michael V Copp, FRCA, Consultant Anaesthetist, Department of Anaesthesia, Cheltenham General Hospital, Sandford Road, Cheltenham, Gloucestershire GL53 7AN, United Kingdom. michael.copp@glos.nhs.uk
Key Words	Sugammadex; Neuromuscular block; Clinical benefits; Patient safety; Cost benefit
Core Tip	Sugammadex is a new drug to reverse neuromuscular blockade. Its unique mechanism of action has revolutionized the management of neuromuscular block. For the first time anaesthetists have the ability to reverse safely and predictably from any level of neuromuscular blockade transforming its clinical management. Post-operative residual curarisation can be eliminated bringing significant safety benefits to patients. Sugammadex is expensive and anaesthetists need to use it in a cost effective way for appropriate patients and anaesthetic techniques. Clinical guidelines can help in ensuring that sugammadex is used responsibly in current clinical practice.
Publish Date	2015-11-26 17:20
Citation	Copp MV, Barrett TF. Sugammadex: Role in current anaesthetic practice and its safety benefits for patients. World J Anesthesiol 2015; 4(3): 66-72
URL	http://www.wjgnet.com/2218-6182/full/v4/i3/66.htm
DOI	http://dx.doi.org/10.5313/wja.v4.i3.66

Full Article (PDF)	WJA-4-66.pdf
Full Article (Word)	WJA-4-66.doc
Manuscript File	19770-Review.docx
Answering Reviewers	19770-Answering reviewers.pdf
Audio Core Tip	19770-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19770-Conflict-of-interest statement.pdf
Copyright License Agreement	19770-Copyright assignment.pdf
Peer-review Report	19770-Peer-review(s).pdf
Scientific Misconduct Check	19770-Scientific misconduct check.pdf
Scientific Editor Work List	19770-Scientific editor work list.pdf